louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04359433: Intermittent Exercise Among Students
Official title: Evaluation the Effectiveness of Intermittent Anaerobic Exercise Among the Students With Cardiometabolic Risk
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Cardiometabolic Risk
Keywords: cardiometabolic
children
Waist to height ratio, WHtR
Intermittent Anaerobic Exercise
Lead sponsor: Children's Hospital of Fudan University
Sponsor class: OTHER
First posted: 2020-04-24
Enrollment: 0
Sex: ALL
Minimum age (years): 6
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Evaluate the effectiveness of intermittency anaerobic exercise interventions among the students with high risk of cardiometabolic .


Eligibility criteria: Inclusion Criterias:

* Male: Waist-to-height ratio≥0.463
* Female： Waist-to-height ratio≥0.469
* Students with cardiometabolic risk factors include elevated BP, dyslipidaemia, elevated fasting blood glucose (FBG) and central obesity.

Exclusion Criterias:

* Participates with severe disease conditions include cardiac insufficiency, respiratory system relate diseases, immunodeficiency or severe malnutrition, ect
* Taking or having taken weight-loss drugs
* Participates unsuitable or improper to participate the study

Primary outcomes:
measure: Abnormal of cardiometabolic risk related index
timeFrame: 3th month after enrollment
Secondary outcomes:
measure: Change of Waist-to-height ratio
timeFrame: Baseline, 12th months after enrollment
measure: Change of Body Mass Index
timeFrame: Baseline, 12th months after enrollment
measure: Change of hipline
timeFrame: Baseline, 12th months after enrollment
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Children's Hospital of Fudan University
Study officials:
affiliation: Children's Hospital of Fudan University
name: Weili Yan, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT01481233: Oral Colchicine in Men With Castrate Resistant Prostate Cancer
Official title: Phase II Trial of Oral Colchicine in Men With Castrate-Resistant Prostate Cancer Who Have Failed Taxotere-Based Chemotherapy
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Prostate Cancer
Keywords: oral colchicine
castrate-resistant prostate cancer
failed taxotere based chemotherapy
Lead sponsor: Milton S. Hershey Medical Center
Sponsor class: OTHER
First posted: 2011-11-29
Enrollment: 0
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the prostate specific antigen response to continuous low dose oral colchicine.

Detailed description: The investigators propose a simple phase II trial of oral colchicine at the standard prophylactic dose utilized for gout in men with CRPCa who have failed taxotere based chemotherapy. The investigators will utilize a simple modified Simon 2-stage design. The investigators plan to enroll 40 men for the study. The men should have completed prior taxotere based therapy or any other therapy post-taxotere including cabazitaxel one month prior to receipt of colchicine on trial. Staging with a baseline bone scan, CT and PSA as well as routine CBC, CMP and PAP. The dose of the drug can be escalated as tolerated to a maximum of 1.2 mg bid. The patient would be seen at 21 day intervals. After every 3 cycles of treatment, patient would be restaged with CT and bone scan. Patients with stable disease, partial response or complete response would continue therapy until either disease progression or intolerable toxicity after which the patient would be taken off study.

Eligibility criteria: Inclusion Criteria:

* Castrate resistant prostate cancer
* Failure or intolerance of taxotere or cabazitaxel-based chemotherapy or abiraterone administered for castrate resistant prostate cancer is allowed
* Age \> 18 years and ability to provide informed consent
* ECOG performance status of 0, 1 or 2
* No prior use of colchicine within the last 2 years
* No chemotherapy, hormonal therapy, immunotherapy or radiation therapy within 1 month of day 1, cycle 1

Exclusion Criteria:

* Inability to provide informed consent
* Hypersensitivity to colchicine
* Severe renal, gastrointestinal or hepatic disorders
* Pre-existing blood dyscrasia
* PLT \< 100K, ANC \< 1000
* Serum Cr \> 2 x ULN
* Bilirubin \> 2 ULN
* AST \> 2 x ULN
* Concurrent use of CYP3A4 inhibitors which may increase drug levels and toxicity

Primary outcomes:
measure: PSA Response rate
timeFrame: 63 days (3 cycles of treatment)
Secondary outcomes:
measure: Response rate
timeFrame: 63 days (3 cycles)
measure: Toxicity grading
timeFrame: One year
Other outcomes:
Locations:
Study officials:
affiliation: Milton S. Hershey Medical Center
name: Joseph J Drabick, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05357833: Novel Imaging Markers in SPMS
Official title: Novel Imaging Markers of Innate Immune Activation in Secondary Progressive Multiple Sclerosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Secondary Progressive Multiple Sclerosis
Multiple Sclerosis, Secondary Progressive
Multiple Sclerosis
Keywords: Perilesional microglia
Ferumoxytol
USPIO
Utrasmall superparamagnetic iron oxide nanoparticles
Infiltrating macrophages
Activated microglia
USPIO enhancement
Lead sponsor: University of Utah
Sponsor class: OTHER
First posted: 2022-05-03
Enrollment: 11
Sex: ALL
Minimum age (years): 35
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This pilot study takes the innovative approach of using ultrasmall superparamagnetic iron oxide (USPIO) nanoparticle enhanced MRI to measure activity of the innate immune system within MS lesions. Activity of innate immunity has been hypothesized as one of the critical pathologic processes underpinning neurologic worsening in progressive MS. As such, in the short term this project proposes to investigate USPIO uptake in SPMS lesions as a promising in vivo imaging biomarker for chronic-active lesions, as distinguished from chronic-inactive lesions.


Eligibility criteria: Inclusion Criteria:

1. Adults age 35 to 65 years
2. Clinically diagnosed with secondary progressive multiple sclerosis (SPMS) (2017 McDonald Criteria)
3. Worsening 25 foot walk time (worsening SPMS cohort) over the preceding 2 years.
4. Ambulatory with ability to walk at least 20 meters without rest, with or without aid
5. Ability and willingness to attend study visits and complete the study

Exclusion Criteria:

1. Clinically diagnosed with relapsing remitting multiple sclerosis (RRMS), primary progressive multiple sclerosis (PPMS), clinical isolated syndrome (CIS), or radiologically isolated syndrome (RIS)
2. Clinical MS relapse and/or new MRI lesion(s) within the preceding 2 years
3. Positive pregnancy test
4. Gadolinium contrast allergy
5. Acute or chronic kidney disease with eGFR \<30 ml/min/1.73m2
6. Pacemaker or other MRI contraindications per American College of Radiology guidelines
7. Intravenous iron sensitivity
8. Serum ferritin and transferrin saturation above age-adjusted upper limit of normal (if serum ferritin is above normal, but transferrin saturation is normal, the subject is NOT excluded)

Primary outcomes:
measure: Signal change on T1-weighted and 3D UTE MRI brain (and upper cervical cord) before and 96 hours (±24 hours) after ferumoxytol administration
timeFrame: 96 hours ±24 hours
Secondary outcomes:
measure: Incidence of treatment-emergent adverse events (safety and tolerability)
timeFrame: 96 hours ±24 hours
Other outcomes:
Locations:
city: Salt Lake City
country: United States
facility: University of Utah Health Imaging and Neurosciences Center
state: Utah
Study officials:
affiliation: University of Utah
name: M. Mateo Paz Soldan, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00901433: Self Operating of the Personal WheezoMeter by Intended Users - A Usability Study
Official title: Self Operating of the Personal WheezoMeter by Intended Users - A Usability Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Asthma
Keywords: Asthma
Wheeze Rate
Respiratory Function Tests
Lead sponsor: KarmelSonix Ltd.
Sponsor class: INDUSTRY
First posted: 2009-05-13
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Male/Female participants ages 18 and up that were either diagnosed as an asthmatic or are parent/guardian of an asthmatic child age under 18 years.

Brief summary: The NAEPP (National Asthma Education and Prevention Program) guidelines recommend that spirometry be performed on patients with asthma because they serve as an objective measure of airway obstruction. Unfortunately, most children under 5 years of age are unable to perform a forced expiratory maneuver making conventional spirometry unavailable in this age group in most venues. Furthermore, other population groups such as retarded people, elderly or physically handicapped share the same difficulty.

Karmel Sonix Ltd has developed the Personal WheezoMeter a hand-held pulmonary sounds analyzer that utilizes contact sensors to acquire, amplify, filter, record and quantify the presence of wheezing. This usability study was designed to test independent home use and device interface effectiveness of the Personal WheezoMeter in order to validate its safe and effective use by intended users.


Eligibility criteria: Inclusion Criteria:

* Male/female age 18 years and up.
* Subject is diagnosed as an asthmatic, or subject is parent/guardian of an asthmatic child age under 18 years.
* Subject understands the study procedure.
* Subject is able to read the User Manual.
* Signed Informed Consent form
* Compliance with study requirements.

Exclusion Criteria:

* Major physical, motor, mental, behavioral, or psychiatric limitations.
* Concurrent additional major illness.
* Subject objects to the study protocol.

Primary outcomes:
measure: Safety will be evaluated by success rate of task performance.
timeFrame: At the end of the study meeting
Secondary outcomes:
measure: Number of questions addressed to the investigator required by the participant in order to complete tasks.
timeFrame: during the study
measure: User satisfaction will be evaluated by questionnaire that focuses on subjective impressions regarding usability and potential safety problems.
timeFrame: At the end of the study meeting.
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: RAMBAM Health Care Campus
Study officials:
affiliation: KarmelSonix Ltd.
name: Hanna Levy, Dr.
role: STUDY_DIRECTOR
References:
Clinical trial NCT02749487: Neutrophil Lymphocyte Ratio as a Predictor of Outcome in Critically Traumatic Patients
Official title: Neutrophil Lymphocyte and Platelet Lymphocyte Ratios as Predictors of Outcome in Traumatic Critically Ill Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Critical Care
Keywords: Critical Care
Neutrophils
Lymphocytes
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2016-04-25
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 80 adult patients who are admitted to critical care unit in Assiut university Hospital

Brief summary: Neutrophil lymphocyte ratio NLR is an important index that evaluate the inflammatory status . It is a cost effective and readily available , and simply calculated , so that why investigators try to use it as a predictor of short term survival in the critically ill patients

Detailed description: NLR will be used as predictor for short term survival and patients stay in ICU in 2 groups of patients . Investigators will use it in a group of Medical Critically ill patients as respiratory failure , neuromuscular disorders , renal impairment . the other group is the critically ill surgical patients , as patients with multiple trauma , post major surgery

Eligibility criteria: Inclusion Criteria:

* Critically ill trauma patients

Exclusion Criteria:

* auto immune disease endocrine disease renal dysfunction hepatic dysfunction malignancy smoking

Primary outcomes:
measure: short term survival
timeFrame: one month
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Emad Zarief Kamel Said
Study officials:
References:
Clinical trial NCT06087887: Association Between Tumor Size and Prognosis in Patients With Small Bowel adenocarcinoma-a SEER-based Study
Official title: Association Between Tumor Size and Prognosis in Patients With Small Bowel adenocarcinoma-a SEER-based Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Prognosis
Lead sponsor: The Third Peoples Hospital of Dalian
Sponsor class: OTHER
First posted: 2023-10-18
Enrollment: 8163
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Data of Small Bowel adenocarcinoma patients from 2004 to 2019 was collected from the SEER database using the SEER\*Stat software (version 8.4.0.1).

Brief summary: The goal of this observational study is to learn about in small bowel adenocarcinoma patients. The main question it aims to answer is the association between tumor size and prognosis in patients with small bowel adenocarcinoma. Participants will be compared for the relationship between tumor size and prognosis.


Eligibility criteria: Inclusion Criteria:

1. pathology confirmed as SBA;
2. received surgery and complete postoperative follow-up data;
3. histology type code 8140-8380.

Exclusion Criteria:

Cases with unknown tumor location, size, TNM staging, race, and degree of differentiation were excluded. Finally, 8,163 eligible patients were included in the analysis

Primary outcomes:
measure: Association Between Tumor Size and Prognosis in Patients With Small Bowel adenocarcinoma-a SEER-based Study
timeFrame: 2024.9.1
Secondary outcomes:
Other outcomes:
Locations:
city: Dalian
country: China
facility: Dalian Third People's Hospital Affiliated to Dalian Medical University
state: Liaoning
Study officials:
References:
Clinical trial NCT01592851: Clinical Efficacy of a Toothpaste in Providing Relief From the Pain of Dentinal Hypersensitivity
Official title: A Clinical Study Investigating the Efficacy of a Dentifrice in Providing Short Term Relief From Dentinal Hypersensitivity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Dentine Hypersensitivity
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2012-05-07
Enrollment: 113
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A study to compare the efficacy of a test dentifrice against a control dentifrice in reducing dentinal hypersensitivity over a two week treatment period.


Eligibility criteria: - Subjects who suffer from tooth sensitivity.

Primary outcomes:
measure: Change From Baseline in Evaporative Air Sensitivity Pain Response on a Schiff Sensitivity Scale at Day 14
timeFrame: Baseline to Day 14
Secondary outcomes:
measure: Change From Baseline in Evaporative Air Sensitivity Pain Response on a Schiff Sensitivity Scale Immediately Post-treatment
timeFrame: Baseline to immediately post treatment administration
measure: Change From Baseline in Evaporative Air Sensitivity Pain Response on a Schiff Sensitivity Scale at Day 3
timeFrame: Baseline to Day 3
measure: Change From Baseline in Tactile Pain Threshold Score at Day 14
timeFrame: Baseline to Day 14
measure: Change From Baseline in Tactile Pain Threshold Score at Day 3
timeFrame: Baseline to Day 3
measure: Change From Baseline in Tactile Pain Threshold Score Immediately Post-treatment
timeFrame: Baseline to immediately post treatment administration
Other outcomes:
Locations:
city: Las Vegas
country: United States
facility: BioSci Research America, Inc.
state: Nevada
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References:
citation: Parkinson CR, Hughes N, Hall C, Whelton H, Gallob J, Mason S. Three randomized clinical trials to assess the short-term efficacy of anhydrous 0.454% w/w stannous fluoride dentifrices for the relief of dentin hypersensitivity. Am J Dent. 2016 Feb;29(1):25-32.
Clinical trial NCT02020551: Lidocaine 10% Spray Reduces Pain During Intrauterine Device Insertion
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain
Keywords: Scores During IUD insertion.
Lead sponsor: Kayseri Education and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2013-12-25
Enrollment: 223
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 49
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Pain during intrauterine device (IUD) insertion can be a barrier to initiation. Misoprostol and nonsteroidal drugs have found to be ineffective by clinical trials.Investigators tested whether intracervical 2% lidocaine gel decreased insertion pain compared to placebo.


Eligibility criteria: Inclusion Criteria:

Age \>18 Not pregnant Smear negative

Exclusion Criteria:

Chronic pelvic pain Pregnancy Uterine anomaly Fibroid Acute cervicitis Pelvic inflammatory disease Cervical stenosis

Primary outcomes:
measure: Pain
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Kayseri
country: Turkey
facility: Kayseri Education and Research Hospital of Medicine
Study officials:
References:
citation: Aksoy H, Aksoy U, Ozyurt S, Acmaz G, Babayigit M. Lidocaine 10% spray to the cervix reduces pain during intrauterine device insertion: a double-blind randomised controlled trial. J Fam Plann Reprod Health Care. 2016 Apr;42(2):83-7. doi: 10.1136/jfprhc-2014-100917. Epub 2015 Mar 10.
Clinical trial NCT02176551: Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects
Official title: A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Product 0405 To A Vehicle Control In The Treatment Of Mild To Moderate Atopic Dermatitis In Pediatric Subjects
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE3
Conditions: Atopic Dermatitis
Lead sponsor: Fougera Pharmaceuticals Inc.
Sponsor class: INDUSTRY
First posted: 2014-06-27
Enrollment: 0
Sex: ALL
Minimum age (years): 3
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and efficacy of product 0405 in pediatric subjects with Mild to Moderate Atopic Dermatitis.

Detailed description: Treatment medication will be administered topically twice daily for 28 days

Eligibility criteria: Inclusion Criteria:

* Clinical Diagnosis of Atopic Dermatitis
* Good health with the exception of Atopic Dermatitis
* Percent body surface area minimum requirements

Exclusion Criteria:

* Subjects who are pregnant, nursing or planning a pregnancy

Primary outcomes:
measure: Statistically significant superiority of the test Product 0405 to the vehicle
timeFrame: 28 days
Secondary outcomes:
measure: Incidence of success based on the Investigators Static Global Assessment and the Clinical Signs and Symptoms (erythema, scaling) at the end of treatment.
timeFrame: 28 days
Other outcomes:
Locations:
Study officials:
affiliation: Fougera Pharmaceuticals Inc.
name: Angela C Kaplan
role: STUDY_DIRECTOR
References:
Clinical trial NCT05556551: Comparing Between Two Different Restoration
Official title: Clinical Performance of Lithium Disilicate Versus Hybrid Resin Ceramic for Inlay and Onlay Restoration After 3 Years Follow up
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dental Restoration Failure
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2022-09-27
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Two different restorations in patient mouth
Primary purpose: TREATMENT

Brief summary: Clinical performance of two different ceramic restoration in patient mouth after 3 years follow up

Detailed description: Comparing two different dental restoration in patient mouth after 3 years follow up by using USPHS criteria

Eligibility criteria: Inclusion Criteria:

* good oral hygiene

Exclusion Criteria:

* bad oral hygiene

Primary outcomes:
measure: Evaluation of two different restoration
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Mansoura
country: Egypt
facility: Amr hany hassan
state: Dakahlia
Study officials:
References:
citation: Rubinstein MH. A new granulation method for compressed tablets [proceedings]. J Pharm Pharmacol. 1976 Dec;28 Suppl:67P. No abstract available.
Clinical trial NCT02352051: Effects of Atx and Oros-mph on Executive Functions
Official title: Effects of Atomoxetine and Oros-mph on Executive Functions in Patients With Combined Type Attention Deficit Hyperactivity Disorder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Executive Dysfunction
Keywords: attention deficit-hyperactivity disorder (ADHD).
executive functions
Lead sponsor: TC Erciyes University
Sponsor class: OTHER
First posted: 2015-02-02
Enrollment: 43
Sex: ALL
Minimum age (years): 7
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study was to evaluate and compare the effects of Atomoxetine(ATX) and osmotic release oral system-methylphenidate (OROS-MPH) therapies on executive functions, activities, treatment response time and adverse effects based on discernible clinical effects in children with combined type attention deficit-hyperactivity disorder (ADHD).

Detailed description: The aim of this study was to evaluate and compare the effects of Atomoxetine(ATX) and osmotic release oral system-methylphenidate (OROS-MPH) therapies on executive functions, activities, treatment response time and adverse effects based on discernible clinical effects in children with combined type attention deficit-hyperactivity disorder (ADHD).

In this study, the functional capabilities of the patients who clinically responded well to therapy were assessed simultaneously with clinical response that may appear at different time periods and the treatment groups were compared in patients who responded to therapy by excluding patients with insufficient clinical response.

Eligibility criteria: Inclusion Criteria:

* Combined type ADHD diagnosis was made by a child psychiatrist according to DSM-IV criteria through K-SADS interview with the patient and mother
* The Clinical Global Impression Scale (CGI-S) was applied to determine ADHD severity and patients with a CGI-S score≥4

Exclusion Criteria:

* Psychological, neurological or psychiatric diseases other than ADHD,
* ADHD types other than combined type,
* Medication that influences cognitive processes or history of such medication,
* WISC-R scores \<80 or \>120

Primary outcomes:
measure: Effects of Atx and Oros-mph on Executive Functions, measured by Wisconsin Card Sorting Test, Stroop Test TBAG Form and Visual Auditory Digit Span B
timeFrame: 20 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: TC Erciyes University
name: bedia ince taşdelen, MD
role: PRINCIPAL_INVESTIGATOR
References: